NutrigeneAI advanced to the finals of the 14th China Innovation and Entrepreneurship Competition (Qianhai Hong Kong–Macao–Taiwan Specialized Track) with its core pipeline, NBL-001, a vascular regenerative cytokine therapy targeting Peripheral Artery Disease (PAD), representing innovation in life and health sciences drug development.
In addition, Professor Jack Wong, Co-founder of NutrigeneAI, received the Excellence in Research Application Award at the 2025 Hong Kong Innovation Entrepreneur Awards, recognizing his contributions to translational research and the application of iPSC-derived endothelial cell platforms for vascular and cardiovascular regeneration.
